STOCK TITAN
  1. Home
  2. News
  3. GOVXW

Geovax Labs Inc - GOVXW STOCK NEWS

Welcome to our dedicated news page for Geovax Labs (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on Geovax Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Geovax Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Geovax Labs's position in the market.

News
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) strengthens its team by appointing Dr. J. Marc Pipas, M.D., as the Executive Medical Director, Oncology, to support the clinical development and regulatory approval of Gedeptin® and other immune-oncology programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin® in patients suffering from advanced head and neck cancer. The study demonstrated safety, tolerability, and stabilization or shrinkage of injected tumors in patients receiving multiple cycles of Gedeptin, leading to expanded development for monotherapy and combination therapy. GeoVax plans to proceed with further Gedeptin investigations, including adjustments to the treatment regimen and combination with immune checkpoint inhibitors in advanced head and neck cancer, as well as for additional cancerous and non-cancerous tumor indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
clinical trial
-
News
GeoVax Announces Issuance of Malaria Vaccine Patent
Rhea-AI Summary
GeoVax Labs, a biotechnology company (Nasdaq: GOVX), has been issued Patent No. 11,857,611 by the U.S. Patent and Trademark Office for a multiple component vaccine to prevent and treat malaria. The patent covers compositions and methods utilizing GeoVax's modified vaccinia Ankara (MVA) vector expressing Plasmodium antigens. The company aims to address the global public health threat of malaria, which causes 227 million infections and 619,000 deaths annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
News
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) to Present at Biotech Showcase and J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
-
News
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) expands its License Agreement with the National Institute of Allergy and Infectious Diseases to include Mpox and smallpox as additional indications for the development of a vaccine against SARS-CoV-2 (COVID-19). The amendment allows GeoVax to use materials and patent rights owned by the National Institutes of Health in combination with the Company’s proprietary technology for the creation of preventive Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccines. The expansion offers the potential for a simplified vaccine regimen for protection against diseases associated with SARS-CoV-2 and orthopoxviruses, providing a significant opportunity for GeoVax's ongoing COVID-19 vaccine program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
covid-19
-
News
GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announced 80% survival in nonhuman primates in recent preclinical studies of its vaccine candidates against Marburg virus and Sudan virus. The presentation at the World Vaccine Congress, West Coast conference, highlighted the potential to protect against Mpox using the MVA vector. Dr. Jason Comer of UTMB delivered the presentation, emphasizing the encouraging results of the MARV vaccine candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
none
News
GeoVax to Participate in Upcoming December Investor Events
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) to Participate in Investor Events to Discuss Corporate Overview, Update, and Next-Generation COVID-19 Vaccine Program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
conferences
-
News
GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress
Rhea-AI Summary
GeoVax Labs, Inc. (GOVX) presented Phase 2 clinical trial data for its next-generation COVID-19 vaccine, GEO-CM04S1, at the World Vaccine Congress, demonstrating potent antibody and cellular immunity in immunocompromised patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
clinical trial covid-19
-
News
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) presents preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine, at the Vaccines Summit 2023 conference. The data demonstrate single-dose protection against multiple SARS-CoV-2 variants, including the Omicron variant, with a focus on inducing both antibodies and T-cell responses. The company is also evaluating its dual antigen COVID-19 vaccine, GEO-CM04S1, in three Phase 2 clinical trials, targeting immunocompromised patients and healthy individuals who have previously received the Pfizer or Moderna mRNA vaccine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
none
News
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announced significant progress in its Phase 2 Program of GEO-CM04S1, a next-generation COVID-19 vaccine. The company presented safe administration and tumor reduction data for Gedeptin® at the AACR-AHNS Head and Neck Cancer Conference. They also secured a multi-product license for ProBioGen's AGE1.CR.pIX® suspension cell line to enhance manufacturing capabilities. The company will host a conference call and webcast today at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
earnings
Stock GOVXW logo
Geovax Labs Inc

Nasdaq:GOVXW

GOVXW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

GOVXW Stock Data

1.89M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Smyrna

About GOVXW

geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.